Medicare's decision to limit coverage for a controversial new Alzheimer's drug has prompted an outcry among Alzheimer's advocates. The drug is Aduhelm, and despite widespread enthusiasm for it among Alzheimer's patients and advocates, it hasn't been proven to slow the disease. The drug was given accelerated approval by the Food and Drug Administration because it reduces the plaque that develops in the brains of most Alzheimer’s patients.
Aduhelm, an expensive Alzheimer's drug, is fomenting controversy — and generating excitement for patients. The FDA approved it last summer. But Adulem’s results are the subject of intense debate — and so is the cost of the drug.